Home Featured Page 255

Featured

Latest

Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names

Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic Public Health

Weekly Psychedelic Policy Briefing: October 5, 2026

Podcast: Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA Moves to Schedule 5 Tryptamines

Psychedelic Churches Need Psychedelic Seminaries

Filament Health Announces Q2 2021 Financial Results

PsyBio Therapeutics Files Patent Application with USPTO for Production Methods of...

More Details on the Psilocybin Mushroom Bluing Reaction

Why Don’t Magic Mushroom Spores Contain Psilocybin?

Mouse Study Reveals New Details on Psilocybin’s Rewiring of the Brain

Is Nitrous Oxide a Psychedelic Drug?

Keeping Participants Safe in Psychedelic Research

In Awe: Psychedelic Assisted Psychotherapy and the Mystical Experience

Myth Busting: Magic Mushroom Spores Have Little to do with Potency

Why Aren’t Psychedelic Drugs Prohibited in the 2021 Tokyo Olympics?

EDITOR PICKS

Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks...

Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic...

Weekly Psychedelic Policy Briefing: October 5, 2026

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names

Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic Public Health

Weekly Psychedelic Policy Briefing: October 5, 2026

Podcast: Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA Moves to Schedule 5 Tryptamines

Psychedelic Churches Need Psychedelic Seminaries

Filament Health Announces Q2 2021 Financial Results

PsyBio Therapeutics Files Patent Application with USPTO for Production Methods of...

More Details on the Psilocybin Mushroom Bluing Reaction

Why Don’t Magic Mushroom Spores Contain Psilocybin?

Mouse Study Reveals New Details on Psilocybin’s Rewiring of the Brain

Is Nitrous Oxide a Psychedelic Drug?

Keeping Participants Safe in Psychedelic Research

In Awe: Psychedelic Assisted Psychotherapy and the Mystical Experience

Myth Busting: Magic Mushroom Spores Have Little to do with Potency

Why Aren’t Psychedelic Drugs Prohibited in the 2021 Tokyo Olympics?

EDITOR PICKS

Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks...

Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic...

Weekly Psychedelic Policy Briefing: October 5, 2026

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY